Physician

Thomas Clayton Williamson, M.D.

According to 2025 Medicare claims, Thomas Williamson, M.D. (NPI: 1023429941) practices hematology/oncology in the Jackson, MS market, with the plurality of this provider's patient population coming from Hinds, MS. This provider's primary affiliated billing organization is JACKSON ONCOLOGY ASSOCIATES (NPI: 1295776136; TIN: 640619700) and primary practice location at 39202-2002. Williamson is affiliated with the Mercy Health Select, LLC (ACO ID: A1215) and Health Leaders Network of Mississippi LLC (ACO ID: A5148), participating under the MSSP model.

Williamson's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 854 traditional Medicare patients, billed 211,995 HCPCS/CPT codes, and received $4,399,624 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,756 prescription claims across 279 beneficiaries totaling $6,030,042 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 61 claims. Open Payments data shows 112 records totaling $47,675. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $4,827 to $4,399,624. Similarly, Part D prescription costs have risen steadily, from $5,805 to $6,030,042. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	35	73	$4,827
2018	19	53	$2,123
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	595	87,052	$1,657,792
2022	850	249,355	$3,401,951
2023	824	246,820	$3,988,742
2024	854	211,995	$4,399,624

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	33	131	$5,805
2016	58	296	$14,827
2017	23	101	$14,269
2018	N/R	11	$1,355
2019	N/R	N/R	N/R
2020	22	49	$2,432
2021	107	345	$868,524
2022	232	1,264	$4,459,169
2023	238	1,442	$4,064,356
2024	279	1,756	$6,030,042

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	51	$2,680
2022	N/R	41	$1,126
2023	N/R	52	$18,069
2024	N/R	61	$1,571

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	495	866	$89
82728	Ferritin (blood protein) level	167	342	$13
80053	Blood test, comprehensive group of blood chemicals	510	1,544	$10
36415	Insertion of needle into vein for collection of blood sample	473	1,463	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	498	1,636	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Imbruvica	Ibrutinib	75	2,168	$916,609
Lenalidomide	Lenalidomide	59	1,463	$755,486
Tagrisso	Osimertinib Mesylate	33	990	$542,342
Brukinsa	Zanubrutinib	35	1,050	$464,554
Revlimid	Lenalidomide	27	693	$436,492

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	26	$1,026
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	23	$395
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$150

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	109	$2,198	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$45,477	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Thomas Clayton Williamson, M.D.?

Tedicare shows public-source Medicare data for Thomas Clayton Williamson, M.D. (NPI 1023429941), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Thomas Clayton Williamson, M.D. have ACO affiliation data?

Thomas Clayton Williamson, M.D. is shown with ACO affiliation data for Mercy Health Select, LLC (MSSP, ACO ID A1215) and Health Leaders Network of Mississippi LLC (MSSP, ACO ID A5148).

What billing organization is linked to Thomas Clayton Williamson, M.D.?

Thomas Clayton Williamson, M.D. is linked to JACKSON ONCOLOGY ASSOCIATES (billing NPI 1295776136) in the available physician profile data.

Does Thomas Clayton Williamson, M.D. have Open Payments data?

Thomas Clayton Williamson, M.D. has 112 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.